Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation

Leukemia Research

Volumn 38, Issue 10, 2014, Pages 1177-1183

  Huang, Bin Tao ^a   Zeng, Qing Chun ^b   Zhao, Wei Hong ^a   Li, Bing Sheng ^c   Chen, Rui lin ^d  

^a AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c Huizhou Medicine Institute   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Essential thrombocythemia; Interferon; JAK2V617F mutation; Polycythemia vera

Indexed keywords

ALPHA2B INTERFERON; HYDROXYUREA; ALPHA INTERFERON; INTERFERON; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; RECOMBINANT PROTEIN;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ERYTHROMELALGIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; JAK2V617F POSITIVE MUTATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUTATION; NAUSEA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PARESTHESIA; PHLEBOTOMY; POLYCYTHEMIA VERA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SKIN DISEASE; THROMBOCYTHEMIA; TREATMENT RESPONSE; VASOMOTOR DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; JAK2V617F MUTATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ESSENTIAL THROMBOCYTHEMIA; INTERFERON; JAK2V617F MUTATION; POLYCYTHEMIA VERA;

ADULT; AGED; FEMALE; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; RECOMBINANT PROTEINS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84908022970     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.06.019     Document Type: Article

References (21)

1. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
2. Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22:14-22.
3. Lacout C., Pisani D.F., Tulliez M., et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108(5):1652-1660.
4. Tefferi A. Annual clinical updates in hematological malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011, 86:292-301.
5. Tefferi A., Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007, 33:313-320.
6. Samuelsson J., Hasselbalch H., Bruserud O., et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006, 106:2397-2405.
7. Harrison C.N., Campbell P.J., Buck G., et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005, 353:33-45.
8. Silver R.T., Kiladjian J.J., Hasselbalch H.C. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013, 6:49-58.
9. Tefferi A., Thiele J., Orazi A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092-1097.
10. Huang B.T., Tan Y., Zhao W.H., Zeng Q.C., Li B.S., Chen R.L. How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study. J Cancer Res Clin Oncol 2014, 140:303-309.
11. Barosi G., Birgegard G., Finazzi G., et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet (ELN) consensus conference. Blood 2009, 113:4829-4833.
12. Quintás-Cardama A., Kantarjian H., Manshouri T., et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009, 27:5418-5424.
13. Kiladjian J.J., Cassinat B., Turlure P., et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006, 108:2037-2040.
14. Najean Y., Rain J.D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997, 90:3370-3377.
15. Kiladjian J.J., Chomienne C., Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008, 22:1990-1998.
16. Larsen T.S., Møller M.B., de Stricker K., et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009, 14:331-334.
17. Quintas-Cardama A., Kantarjian H., Manshouri T., et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009, 27:5418-5424.
18. Kiladjian J.J., Cassinat B., Chevret S., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112:3065-3072.
19. Crisa E., Venturino E., Passera R., et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol 2010, 89:691-699.
20. Barbui T., Finazzi M.C., Finazzi G. Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 2012, 26:205-211.
21. Silver R.T. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006, 107:451-458.